Although immunotherapy has recently revolutionized standard of care in different cancer types, prostate cancer has generally failed to show dramatic responses to immune checkpoint inhibitors. As in other tumors, the goal in prostate cancer is now to target treatments more precisely on patient's individual characteristics through precision medicine. Defects in mismatch repair, mutations in the exonuclease domain of the DNA polymerase epsilon (POLE), high tumor mutational burden and the presence of biallelic loss of CDK12 among others, are predictive biomarkers of response to immunotherapy. In the present review, we summarize the evolving landscape of immunotherapy in prostate cancer, including precision approaches and strategies to define classes of responsive patients and scale up resistance to immune checkpoint inhibitors.

Biomarker-driven immunotherapy for precision medicine in prostate cancer / A. Ottini, P. Sepe, T. Beninato, M. Claps, V. Guadalupi, E. Verzoni, P. Giannatempo, G. Baciarello, F. De Braud, G. Procopio. - In: PERSONALIZED MEDICINE. - ISSN 1741-0541. - 19:1(2022), pp. 51-66. [10.2217/pme-2021-0079]

Biomarker-driven immunotherapy for precision medicine in prostate cancer

Ottini A.;Sepe P.;Beninato T.;Verzoni E.;Giannatempo P.;De Braud F.;Procopio G.
2022

Abstract

Although immunotherapy has recently revolutionized standard of care in different cancer types, prostate cancer has generally failed to show dramatic responses to immune checkpoint inhibitors. As in other tumors, the goal in prostate cancer is now to target treatments more precisely on patient's individual characteristics through precision medicine. Defects in mismatch repair, mutations in the exonuclease domain of the DNA polymerase epsilon (POLE), high tumor mutational burden and the presence of biallelic loss of CDK12 among others, are predictive biomarkers of response to immunotherapy. In the present review, we summarize the evolving landscape of immunotherapy in prostate cancer, including precision approaches and strategies to define classes of responsive patients and scale up resistance to immune checkpoint inhibitors.
biomarkers; immune checkpoint inhibitors; immunotherapy; precision medicine; prostate cancer; Biomarkers; DNA Mismatch Repair; Humans; Immunotherapy; Male; Precision Medicine; Prostatic Neoplasms
Settore MED/06 - Oncologia Medica
7-dic-2021
PERSONALIZED MEDICINE
Article (author)
File in questo prodotto:
File Dimensione Formato  
pme-2021-0079.pdf

non disponibili

Tipologia: Publisher's version/PDF
Dimensione 1.11 MB
Formato Adobe PDF
1.11 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/910547
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact